2548 research outputs found
Sort by
Sixty-Two Percent of Abstracts from the American Association of Hand Surgery Annual Meeting 2017-2020 Are Later Published
Get PDFBeyond the Norm: Brucellosis Defying Convention as Gram-Positive Cocci in Chains Masquerading as Infectious Mononucleosis
No full textRare Incidental and Asymptomatic Fistula Between the Sinus of Valsalva and the Right Ventricle
No full textHypotension in the Emergency Department and contrast dye extravasation predict blood transfusion in low-energy pelvic fractures
No full text
Provider Use and Comfortability with Standardized Mental Health Screeners in a Large Pediatric Urban Academic Medical center
Get PDF
Spinal Cord Stimulation and Intrathecal Drug Delivery System Therapy in a Pregnant Patient with Complex Regional Pain Syndrome Type II: A Case Report
No full textBackground: Complex Regional Pain Syndrome (CRPS) is a difficult-to-treat chronic pain condition. When indicated, spinal cord stimulator (SCS) therapy can serve as a solution. Rarely, intrathecal drug delivery system (IDDS) can be used with SCS to enhance analgesia. Given women’s predisposition towards CRPS, there may be an increasing co-existence of pregnancy and CRPS. Case Report: A pregnant woman presented with right lower extremity pain due to CRPS type II. Here, we present the first case of a woman who continued SCS and IDDS therapies throughout pregnancy. She had an uncomplicated pregnancy, labor, and delivery. The baby achieved all developmental milestones at one year. Conclusion: Further research on the safety of SCS and IDDS during pregnancy is required to determine their effects on the mother and fetus. Until then, the decision to continue these therapies should be considered individually and with close collaboration among the patient, obstetrics, and pain management teams
Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
No full textBACKGROUND: Semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has shown promise in weight management and cardiovascular outcomes in other populations. This study aimed to evaluate the efficacy of semaglutide in heart failure with preserved ejection fraction (HFpEF) patients with obesity.
METHODS: A retrospective study analyzed 318 patients with HFpEF, of which 104 received semaglutide and 214 received placebo. Primary endpoints included evaluating changes in exercise capacity and weight management.
RESULTS: Semaglutide treatment led to significant improvements in the primary endpoints. Patients in the semaglutide group demonstrated substantial enhancements in exercise capacity, as measured by the 6-min walk distance, compared to the placebo group (mean difference 15.1 meters, 95% CI 5.8 to 24.4, p = 0.002). Additionally, semaglutide resulted in substantial weight loss compared to placebo (mean difference -2.9%, 95% CI -4.1--1.7, p = 0.001). Several secondary endpoints, including reductions in C-reactive protein levels and improvements in other clinical parameters, further supported the efficacy of semaglutide. Adverse events were generally well-tolerated, with no unexpected safety concerns.
CONCLUSION: Semaglutide demonstrated significant clinical benefits in HFpEF patients with obesity, as evidenced by improved symptoms, physical function, and weight reduction